RxDoctor Payments Data

Ralph Conaway Lanuza, MD

Cardiology · Hato Rey, PRNPI 1043216401

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 106 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 12 manufacturers reported payments, led by Boehringer Ingelheim at 25.4% of the total. Reporting peaked in 2020 at $591 and has fallen 84.9% since, to $90 in 2025.

$2,261in general payments, 2019–2025

Across 106 payments — averaging $21.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$574
  • E.r. Squibb & Sons, L.L.C.$474
  • PBG Puerto Rico LLC$449
  • Johnson & Johnson$332
  • Amgen$193
  • GSK$69
  • plus $170 from 6 others

What the payments were for

  • Food & beverage$2,261100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Boehringer Ingelheim28$574
E.r. Squibb & Sons, L.L.C.20$474
PBG Puerto Rico LLC22$449
Johnson & Johnson14$332
Amgen10$193
GSK3$69
Merck3$57
AstraZeneca2$29
Novartis1$25
Pfizer1$24
Pfizer Pharmaceuticals LLC1$20
Sanofi-aventis U.S. LLC1$15

How this compares

Too few cardiology providers in Puerto Ricoto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$31,495
Medicare patients
117
Services billed
532

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban32$46,500
XareltoRivaroxaban13$15,227
SynthroidLevothyroxine Sodium143$14,807
Losartan Potassium359$4,942
Metoprolol Succinate187$4,239
Candesartan Cilexetil27$3,738
Rosuvastatin Calcium163$2,876
Candesartan-HydrochlorothiazidCandesartan/Hydrochlorothiazid14$2,505
Atorvastatin Calcium170$2,283
PremarinEstrogens, Conjugated11$2,170
Simvastatin156$1,935
Amlodipine Besylate266$1,819
FenofibrateFenofibrate Nanocrystallized41$1,572
Enalapril Maleate44$1,550
Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide20$1,361

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Premarin$24$48,67143 claims
Johnson & JohnsonXarelto$332$15,22713 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few cardiology providers in Puerto Ricoon file to place this against a meaningful peer group, so we don't.

Other cardiology in Hato Rey

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →